NOS2 and COX2 Provide Key Spatial Targets That Determine Outcome in ER- Breast Cancer

Overview

Journal bioRxiv

Date 2024 Jan 8

PMID 38187532

Authors

Lisa A Ridnour

William F Heinz

Robert Ys Cheng

Adelaide L Wink

Noemi Kedei

Milind Pore

Fatima Imtiaz

Elise L Femino

Ana L Gonzalez

Leandro Coutinho

Donna Butcher

Elijah F Edmondson

M Cristina Rangel

Robert J Kinders

Stanley Lipkowitz

Stephen Tc Wong

Stephen K Anderson

Danial W McVicar

Xiaoxian Li

Sharon A Glynn

Timothy R Billiar

Jenny C Chang

Stephen M Hewitt

Stefan Ambs

Stephen J Lockett

David A Wink

Affiliations

Soon will be listed here.

Abstract

Estrogen receptor-negative (ER-) breast cancer is an aggressive breast cancer subtype with limited therapeutic options. Upregulated expression of both inducible nitric oxide synthase (NOS2) and cyclo-oxygenase (COX2) in breast tumors predicts poor clinical outcomes. Signaling molecules released by these enzymes activate oncogenic pathways, driving cancer stemness, metastasis, and immune suppression. The influence of tumor NOS2/COX2 expression on the landscape of immune markers using multiplex fluorescence imaging of 21 ER- breast tumors were stratified for survival. A powerful relationship between tumor NOS2/COX2 expression and distinct CD8+ T cell phenotypes was observed at 5 years post-diagnosis. These results were confirmed in a validation cohort using gene expression data showing that ratios of NOS2 to CD8 and COX2 to CD8 are strongly associated with poor outcomes in high NOS2/COX2-expressing tumors. Importantly, multiplex imaging identified distinct CD8+ T cell phenotypes relative to tumor NOS2/COX2 expression in Deceased vs Alive patient tumors at 5-year survival. CD8+NOS2-COX2- phenotypes defined fully inflamed tumors with significantly elevated CD8+ T cell infiltration in Alive tumors expressing low NOS2/COX2. In contrast, two distinct phenotypes including inflamed CD8+NOS2+COX2+ regions with stroma-restricted CD8+ T cells and CD8-NOS2-COX2+ immune desert regions with abated CD8+ T cell penetration, were significantly elevated in Deceased tumors with high NOS2/COX2 expression. These results were supported by applying an unsupervised nonlinear dimensionality-reduction technique, UMAP, correlating specific spatial CD8/NOS2/COX2 expression patterns with patient survival. Moreover, spatial analysis of the CD44v6 and EpCAM cancer stem cell (CSC) markers within the CD8/NOS2/COX2 expression landscape revealed positive correlations between EpCAM and inflamed stroma-restricted CD8+NOS2+COX2+ phenotypes at the tumor/stroma interface in deceased patients. Also, positive correlations between CD44v6 and COX2 were identified in immune desert regions in deceased patients. Furthermore, migrating tumor cells were shown to occur only in the CD8-NOS2+COX2+ regions, identifying a metastatic hot spot. Taken together, this study shows the strength of spatial localization analyses of the CD8/NOS2/COX2 landscape, how it shapes the tumor immune microenvironment and the selection of aggressive tumor phenotypes in distinct regions that lead to poor clinical outcomes. This technique could be beneficial for describing tumor niches with increased aggressiveness that may respond to clinically available NOS2/COX2 inhibitors or immune-modulatory agents.

References

Somasundaram V, Ridnour L, Cheng R, Walke A, Kedei N, Bhattacharyya D . Systemic Nos2 Depletion and Cox inhibition limits TNBC disease progression and alters lymphoid cell spatial orientation and density. Redox Biol. 2022; 58:102529. PMC: 9661390. DOI: 10.1016/j.redox.2022.102529. View

Wink D, Grisham M, Mitchell J, Ford P . Direct and indirect effects of nitric oxide in chemical reactions relevant to biology. Methods Enzymol. 1996; 268:12-31. DOI: 10.1016/s0076-6879(96)68006-9. View

Uddin M, Crews B, Blobaum A, Kingsley P, Gorden D, McIntyre J . Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents. Cancer Res. 2010; 70(9):3618-27. PMC: 2864539. DOI: 10.1158/0008-5472.CAN-09-2664. View

Bauer K, Brown M, Cress R, Parise C, Caggiano V . Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007; 109(9):1721-8. DOI: 10.1002/cncr.22618. View

Manesse M, Patel K, Bobrow M, Downing S . The InSituPlex Staining Method for Multiplexed Immunofluorescence Cell Phenotyping and Spatial Profiling of Tumor FFPE Samples. Methods Mol Biol. 2019; 2055:585-592. DOI: 10.1007/978-1-4939-9773-2_26. View

Tai H, Chi X, Tong M . Regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by non-steroidal anti-inflammatory drugs (NSAIDs). Prostaglandins Other Lipid Mediat. 2011; 96(1-4):37-40. DOI: 10.1016/j.prostaglandins.2011.06.005. View

Somasundaram V, Gilmore A, Basudhar D, Palmieri E, Scheiblin D, Heinz W . Inducible nitric oxide synthase-derived extracellular nitric oxide flux regulates proinflammatory responses at the single cell level. Redox Biol. 2019; 28:101354. PMC: 6920088. DOI: 10.1016/j.redox.2019.101354. View

Giraldo N, Berry S, Becht E, Ates D, Schenk K, Engle E . Spatial UMAP and Image Cytometry for Topographic Immuno-oncology Biomarker Discovery. Cancer Immunol Res. 2021; 9(11):1262-1269. PMC: 8610079. DOI: 10.1158/2326-6066.CIR-21-0015. View

Chen L, Yang P, Haq A, Hwang P, Lai Y, Weng Y . Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice. J Biomed Sci. 2022; 29(1):70. PMC: 9479298. DOI: 10.1186/s12929-022-00855-6. View

10.

Chung A, Anand K, Anselme A, Chan A, Gupta N, Venta L . A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer. Sci Transl Med. 2021; 13(624):eabj5070. DOI: 10.1126/scitranslmed.abj5070. View

11.

Glynn S, Boersma B, Dorsey T, Yi M, Yfantis H, Ridnour L . Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Invest. 2010; 120(11):3843-54. PMC: 2964971. DOI: 10.1172/JCI42059. View

12.

Kalinski P . Regulation of immune responses by prostaglandin E2. J Immunol. 2011; 188(1):21-8. PMC: 3249979. DOI: 10.4049/jimmunol.1101029. View

13.

Cheng R, Ridnour L, Wink A, Gonzalez A, Femino E, Rittscher H . Interferon-gamma is quintessential for NOS2 and COX2 expression in ER breast tumors that lead to poor outcome. Cell Death Dis. 2023; 14(5):319. PMC: 10175544. DOI: 10.1038/s41419-023-05834-9. View

14.

Basudhar D, Glynn S, Greer M, Somasundaram V, No J, Scheiblin D . Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer. Proc Natl Acad Sci U S A. 2017; 114(49):13030-13035. PMC: 5724261. DOI: 10.1073/pnas.1709119114. View

15.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

16.

Wu Q, Wang J, Liu Y, Gong X . Epithelial cell adhesion molecule and epithelial-mesenchymal transition are associated with vasculogenic mimicry, poor prognosis, and metastasis of triple negative breast cancer. Int J Clin Exp Pathol. 2020; 12(5):1678-1689. PMC: 6947126. View

17.

Gruosso T, Gigoux M, Manem V, Bertos N, Zuo D, Perlitch I . Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. J Clin Invest. 2019; 129(4):1785-1800. PMC: 6436884. DOI: 10.1172/JCI96313. View

18.

Ibrahim E, Al-Foheidi M, Al-Mansour M, Kazkaz G . The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis. Breast Cancer Res Treat. 2014; 148(3):467-76. DOI: 10.1007/s10549-014-3185-2. View

19.

Glynn S, Prueitt R, Ridnour L, Boersma B, Dorsey T, Wink D . COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer. BMC Cancer. 2010; 10:626. PMC: 2993681. DOI: 10.1186/1471-2407-10-626. View

20.

Li J, Zha X, Wang R, Li X, Xu B, Xu Y . Regulation of CD44 expression by tumor necrosis factor-α and its potential role in breast cancer cell migration. Biomed Pharmacother. 2012; 66(2):144-50. DOI: 10.1016/j.biopha.2011.11.021. View